SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02089555
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
African Americans are twice as likely to develop Alzheimer's disease as white Americans, but
few African Americans are enrolled in large Alzheimer's biomarker studies. The current
proposal aims to determine the influence of Alzheimer's disease and vascular disease on
memory and aging in African Americans through modern biomarkers (spinal fluid, MRI, and
amyloid imaging), and how these may differ between African Americans and white Americans in
preparation for a large multi-center study of aging in African American.
Name: Lumbar puncture
Description: Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
Type: Procedure
Group Labels: 2 African Americans Non-Hispanic Whites
Name: Blood draw
Description: One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
Type: Procedure
Group Labels: 2 African Americans Non-Hispanic Whites
Name: Magnetic Resonance Imaging (MRI)
Description: Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
Type: Procedure
Group Labels: 2 African Americans Non-Hispanic Whites
Primary Outcomes
Measure: CSF endothelial marker levels Time: one time only
Measure: CSF Alzheimer's biomarker levels Time: one time only
Secondary Outcomes
Measure: MRI evidence of small vessel disease Time: one time only
Measure: MRI evidence of brain atrophy Time: one time only
Time Perspective: Prospective
Case Control
There is one SNP
SNPs
1 K56M
The Lys56Met ICAM1 gene variant associated
with low ICAM-1 levels is uniquely found in 16-20% of AA, and these subjects may have
impaired downstream activation of neprilysin, an Abeta-degrading enzyme. --- Lys56Met ---
If the hypothesis is
true, AA subjects with the Lys56Met gene variant will be more likely to have hippocampal
atrophy, temporal-parietal cerebral hypoperfusion, and cerebral amyloid deposition than AA
subjects and NHW subjects without the gene variant. --- Lys56Met ---
HPO Nodes
HPO: Protein Mutations 0
SNP 0